|Bid||2.8100 x 2200|
|Ask||2.8100 x 1100|
|Day's Range||2.7600 - 3.1800|
|52 Week Range||2.7600 - 9.8100|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.83|
Subscribe to Yahoo Finance Plus to view Fair Value for JNCE
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference: Presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET. Cowen’s 3rd Annual Oncology Inn
The analysts covering Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) delivered a dose of negativity to shareholders today...
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Imagine if you held Jounce...